Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIKACHU: Treatment Strategies for NSCLC with Oncogenic Mutations
NCT04322890Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Apr 2020
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of osimertinib, alectinib, crizotinib, savolitinib, pemetrexed and 1 more in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Started Apr 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04322890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322890.